|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ANKRD46 |
Gene summary for ANKRD46 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ANKRD46 | Gene ID | 157567 |
| Gene name | ankyrin repeat domain 46 | |
| Gene Alias | ANK-S | |
| Cytomap | 8q22.3 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | A0A024R9E1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 157567 | ANKRD46 | LZE2T | Human | Esophagus | ESCC | 2.63e-12 | 1.11e+00 | 0.082 |
| 157567 | ANKRD46 | LZE4T | Human | Esophagus | ESCC | 4.20e-13 | 3.96e-01 | 0.0811 |
| 157567 | ANKRD46 | LZE8T | Human | Esophagus | ESCC | 1.44e-03 | 1.48e-01 | 0.067 |
| 157567 | ANKRD46 | LZE20T | Human | Esophagus | ESCC | 1.94e-08 | 2.42e-01 | 0.0662 |
| 157567 | ANKRD46 | LZE24T | Human | Esophagus | ESCC | 7.16e-08 | 1.93e-01 | 0.0596 |
| 157567 | ANKRD46 | LZE21T | Human | Esophagus | ESCC | 3.46e-05 | 3.03e-01 | 0.0655 |
| 157567 | ANKRD46 | P1T-E | Human | Esophagus | ESCC | 1.23e-03 | 2.03e-01 | 0.0875 |
| 157567 | ANKRD46 | P2T-E | Human | Esophagus | ESCC | 3.65e-21 | 3.66e-01 | 0.1177 |
| 157567 | ANKRD46 | P4T-E | Human | Esophagus | ESCC | 3.61e-14 | 3.79e-01 | 0.1323 |
| 157567 | ANKRD46 | P5T-E | Human | Esophagus | ESCC | 3.05e-10 | 2.45e-01 | 0.1327 |
| 157567 | ANKRD46 | P8T-E | Human | Esophagus | ESCC | 8.49e-11 | 1.94e-01 | 0.0889 |
| 157567 | ANKRD46 | P9T-E | Human | Esophagus | ESCC | 1.72e-05 | 1.76e-01 | 0.1131 |
| 157567 | ANKRD46 | P10T-E | Human | Esophagus | ESCC | 3.54e-20 | 3.19e-01 | 0.116 |
| 157567 | ANKRD46 | P11T-E | Human | Esophagus | ESCC | 9.09e-07 | 2.32e-01 | 0.1426 |
| 157567 | ANKRD46 | P12T-E | Human | Esophagus | ESCC | 8.72e-29 | 4.77e-01 | 0.1122 |
| 157567 | ANKRD46 | P15T-E | Human | Esophagus | ESCC | 9.14e-09 | 1.84e-01 | 0.1149 |
| 157567 | ANKRD46 | P16T-E | Human | Esophagus | ESCC | 6.28e-38 | 7.15e-01 | 0.1153 |
| 157567 | ANKRD46 | P17T-E | Human | Esophagus | ESCC | 1.68e-03 | 2.03e-01 | 0.1278 |
| 157567 | ANKRD46 | P19T-E | Human | Esophagus | ESCC | 4.34e-03 | 4.44e-01 | 0.1662 |
| 157567 | ANKRD46 | P20T-E | Human | Esophagus | ESCC | 1.72e-14 | 2.60e-01 | 0.1124 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ANKRD46 | SNV | Missense_Mutation | c.22N>A | p.Asp8Asn | p.D8N | Q86W74 | protein_coding | tolerated_low_confidence(0.36) | probably_damaging(0.971) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ANKRD46 | SNV | Missense_Mutation | novel | c.514G>A | p.Gly172Ser | p.G172S | Q86W74 | protein_coding | tolerated(0.21) | benign(0.003) | TCGA-BH-A18T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| ANKRD46 | insertion | Nonsense_Mutation | novel | c.369_370insTAACAGAAA | p.Asp123_Val124insTer | p.D123_V124ins* | Q86W74 | protein_coding | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | ||
| ANKRD46 | insertion | Frame_Shift_Ins | novel | c.367_368insCT | p.Asp123AlafsTer15 | p.D123Afs*15 | Q86W74 | protein_coding | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | ||
| ANKRD46 | insertion | In_Frame_Ins | novel | c.359_360insGCAACTTGAACTTTATATAGG | p.Val120_Asn121insGlnLeuGluLeuTyrIleGly | p.V120_N121insQLELYIG | Q86W74 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| ANKRD46 | insertion | Frame_Shift_Ins | novel | c.312_313insCATTCTTTTTGTGACCTGTACTTAA | p.Asn105HisfsTer26 | p.N105Hfs*26 | Q86W74 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
| ANKRD46 | SNV | Missense_Mutation | novel | c.233N>A | p.Gly78Glu | p.G78E | Q86W74 | protein_coding | deleterious(0) | possibly_damaging(0.597) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| ANKRD46 | SNV | Missense_Mutation | novel | c.356N>C | p.Gly119Ala | p.G119A | Q86W74 | protein_coding | deleterious(0.03) | probably_damaging(0.981) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| ANKRD46 | SNV | Missense_Mutation | rs765571492 | c.122N>A | p.Arg41His | p.R41H | Q86W74 | protein_coding | tolerated(0.09) | possibly_damaging(0.595) | TCGA-G4-6309-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | PD |
| ANKRD46 | SNV | Missense_Mutation | novel | c.208N>A | p.Asp70Asn | p.D70N | Q86W74 | protein_coding | tolerated(0.09) | probably_damaging(0.993) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |